These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 7536693)

  • 1. Suppression of follicular phase pituitary-gonadal function by a potent new gonadotropin-releasing hormone antagonist with reduced histamine-releasing properties (ganirelix).
    Nelson LR; Fujimoto VY; Jaffe RB; Monroe SE
    Fertil Steril; 1995 May; 63(5):963-9. PubMed ID: 7536693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of a GnRH antagonist on follicle maturation in normal women.
    Pousias S; Messini CI; Anifandis G; Sveronis G; Georgoulias P; Daponte A; Messinis IE; Dafopoulos K
    Reprod Biomed Online; 2019 Jul; 39(1):84-92. PubMed ID: 31129014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-related suppression of serum luteinizing hormone in women by a potent new gonadotropin-releasing hormone antagonist (Ganirelix) administered by intranasal spray.
    Fujimoto VY; Monroe SE; Nelson LR; Downey D; Jaffe RB
    Fertil Steril; 1997 Mar; 67(3):469-73. PubMed ID: 9091332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers.
    Oberyé JJ; Mannaerts BM; Huisman JA; Timmer CJ
    Fertil Steril; 1999 Dec; 72(6):1006-12. PubMed ID: 10593372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LH suppression following different low doses of the GnRH antagonist ganirelix in polycystic ovary syndrome.
    Hohmann FP; Laven JS; Mulders AG; Oberyé JJ; Mannaerts BM; de Jong FH; Fauser BC
    J Endocrinol Invest; 2005 Dec; 28(11):990-7. PubMed ID: 16483177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variable tolerance of the developing follicle and corpus luteum to gonadotropin-releasing hormone antagonist-induced gonadotropin withdrawal in the human.
    Hall JE; Bhatta N; Adams JM; Rivier JE; Vale WW; Crowley WF
    J Clin Endocrinol Metab; 1991 May; 72(5):993-1000. PubMed ID: 1902489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single injection of a gonadotropin-releasing hormone (GnRH) antagonist (Cetrorelix) postpones the luteinizing hormone (LH) surge: further evidence for the role of GnRH during the LH surge.
    Leroy I; d'Acremont M; Brailly-Tabard S; Frydman R; de Mouzon J; Bouchard P
    Fertil Steril; 1994 Sep; 62(3):461-7. PubMed ID: 8062939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
    Kazem R; Messinis LE; Fowler P; Groome NP; Knight PG; Templeton AA
    Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mode of suppression of pituitary and gonadal function after acute or prolonged administration of a luteinizing hormone-releasing hormone antagonist in normal men.
    Pavlou SN; Wakefield G; Schlechter NL; Lindner J; Souza KH; Kamilaris TC; Konidaris S; Rivier JE; Vale WW; Toglia M
    J Clin Endocrinol Metab; 1989 Feb; 68(2):446-54. PubMed ID: 2537334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pituitary-ovarian relationships preceding the menopause. I. A cross-sectional study of serum follice-stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone levels.
    Reyes FI; Winter JS; Faiman C
    Am J Obstet Gynecol; 1977 Nov; 129(5):557-64. PubMed ID: 910845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation.
    European and Middle East Orgalutran Study Group
    Hum Reprod; 2001 Apr; 16(4):644-51. PubMed ID: 11278211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of estrogen and progesterone on the functional capacity of the gonadotrophs.
    Lasley BL; Wang CF; Yen SS
    J Clin Endocrinol Metab; 1975 Nov; 41(5):820-6. PubMed ID: 1102551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group.
    Hum Reprod; 1998 Nov; 13(11):3023-31. PubMed ID: 9853849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells.
    Minaretzis D; Alper MM; Oskowitz SP; Lobel SM; Mortola JF; Pavlou SN
    Am J Obstet Gynecol; 1995 May; 172(5):1518-25. PubMed ID: 7755066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variable ovarian response to gonadotropin-releasing hormone antagonist-induced gonadotropin deprivation during different phases of the menstrual cycle.
    Fluker MR; Marshall LA; Monroe SE; Jaffe RB
    J Clin Endocrinol Metab; 1991 Apr; 72(4):912-9. PubMed ID: 2005218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Follicular arrest during the midfollicular phase of the menstrual cycle: a gonadotropin-releasing hormone antagonist imposed follicular-follicular transition.
    Kettel LM; Roseff SJ; Chiu TC; Bangah ML; Vale W; Rivier J; Burger HG; Yen SS
    J Clin Endocrinol Metab; 1991 Sep; 73(3):644-9. PubMed ID: 1908486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypersensitivity of the human gonadotrophs to the repeated administration of small doses of LH-RH.
    Faure N; Olivier GC
    Horm Res; 1978; 9(1):12-21. PubMed ID: 338460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of short-term cyclic administration of cyproterone acetate on pituitary-ovarian function in the human.
    Kumari GI; Das RP; Madoiya KK; Jain AK; Roy S
    Fertil Steril; 1977 Nov; 28(11):1168-74. PubMed ID: 562781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a superactive luteinizing hormone-releasing factor agonist on gonadotropin and ovarian function during the menstrual cycle.
    Sheehan KL; Casper RF; Yen SS
    Am J Obstet Gynecol; 1979 Nov; 135(6):759-63. PubMed ID: 386801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
    de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.